Readout adds veteran executive leadership to its management team ST. LOUIS – Readout, an early-stage digital health company, announced completion of its initial funding round, led by BioGenerator, the investment […]
Read MoreAdarza BioSystems to reveal ZIVA platform at AAI 2019: a fully automated protein multiplex detection system ST. LOUIS (May 2, 2019) — Biotech startup Adarza Biosystems, Inc. announced today that […]
Read MorePress release: https://canopybiosciences.com/news/canopy-biosciences-acquires-zellkraftwerk-gmbh/ Acquisition gives St. Louis-based Canopy an international reach Article by David Nicklaus Expanding internationally, being backed by a prominent private equity firm and tripling in size […]
Read MoreIndalo Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead Antifibrotic Drug Candidate IDL-2965 – Oral integrin antagonist inhibits multiple processes of pathologic fibrosis – Indalo to present at […]
Read MorePosition Summary: Reporting to the President and CEO, this senior advancement professional is responsible for all outcomes and activities associated with fundraising and donor relations with private donors, corporations, foundations, […]
Read MoreBRISBANE, Calif. and ST. LOUIS–(BUSINESS WIRE)–Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced a successful $50 million Series […]
Read MoreST. LOUIS, MO—March 19, 2019—Benson Hill Biosystems, a crop improvement company unlocking the natural diversity of plants, announced today at the World Agri-Tech Innovation Summit that it has acquired the […]
Read MoreBioGenerator-supported startup noted for its ‘promising process’ to more quickly and affordably bring vaccines to market St. Louis bioscience startup VaxNewMo is developing broader and more affordable vaccines faster with […]
Read MoreArch Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of AO-176, an Anti-CD47 Antibody with a Best-in-class Profile — Phase 1 Clinical Trial to Evaluate AO-176 for the […]
Read MoreArvegenix Changes Name to CoverCress Inc.; Secures $2 Million in New Financing for Novel Crop Development ST. LOUIS (Nov. 14, 2018) – CoverCress Inc. (formerly Arvegenix Inc.), recently closed a $2 […]
Read More